重组与血浆源性凝血因子VIII浓缩物中抑制物发生的时间与严重程度:一项SIPPET分析
该SIPPET事后分析按每5个暴露日(ED)评估重型血友病A初治患者中抑制物的发生情况,发现rFVIII组抑制物发生率高于pdFVIII组,且发生更早、峰值更高;rFVIII组最高发时段为前10个ED,前5个ED内所有抑制物风险比3.14(95%CI 1.01-9.74),高滴度抑制物风险比4.19(95%CI 1.18-14.8)。
要点
- rFVIII组抑制物发生率高于pdFVIII组,且发生时间更早、峰值更高。
- 前5个ED内,rFVIII组所有抑制物风险比3.14(95%CI 1.01-9.74)。
- 前5个ED内,rFVIII组高滴度抑制物风险比4.19(95%CI 1.18-14.8)。
核心结论
- 结果强调患者在接受FVIII浓缩物最早暴露期间免疫脆弱性高,对重组FVIII产品的反应最强。
研究设计与样本
- SIPPET试验的事后分析,按每5个暴露日(从0到50个ED)评估不同类别FVIII产品治疗患者的抑制物发生率。
主要发现
- 抑制物发生率最高出现在前10个ED,前5个ED内rFVIII与pdFVIII差异大:所有抑制物风险比3.14(95%CI 1.01-9.74),高滴度抑制物风险比4.19(95%CI 1.18-14.8)。
- pdFVIII组抑制物发生峰值较晚(6-10个ED)且持续时间较短。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Recombinant factor VIII (rFVIII) was contrasted with plasma-derived FVIII (pdFVIII). In previously untreated patients with hemophilia A, rFVIII led to more inhibitors than pdFVIII. Inhibitors with rFVIII developed earlier, and the peak rate was higher than with pdFVIII. Inhibitors with rFVIII were more severe (higher titre) than with pdFVIII. SUMMARY: Background The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is the most severe complication in the early phases of treatment of severe hemophilia A. Recently, a randomized trial, the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) demonstrated a 2-fold higher risk of inhibitor development in children treated with recombinant FVIII (rFVIII) products than with plasma-derived FVIII (pdFVIII) during the first 50 exposure days (EDs). Objective/Methods In this post-hoc SIPPET analysis we evaluated the rate of inhibitor incidence over time by every 5 EDs (from 0 to 50 EDs) in patients treated with different classes of FVIII product, made possible by a frequent testing regime. Results The highest rate of inhibitor development occurred in the first 10 EDs, with a large contrast between rFVIII and pdFVIII during the first 5 EDs: hazard ratio 3.14 (95% confidence interval [CI], 1.01-9.74) for all inhibitors and 4.19 (95% CI, 1.18-14.8) for high-titer inhibitors. For patients treated with pdFVIII, the peak of inhibitor development occurred later (6-10 EDs) and lasted for a shorter time. Conclusion These results emphasize the high immunologic vulnerability of patients during the earliest exposure to FVIII concentrates, with the strongest response to recombinant FVIII products.
引用
- Peyvandi F, Cannavò A, Garagiola I, et al. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2017. PMID: 29080391. doi:10.1111/jth.13888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。